<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766465</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1503</org_study_id>
    <secondary_id>1U01HL128568-01</secondary_id>
    <nct_id>NCT02766465</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)</brief_title>
  <acronym>STRIDE2</acronym>
  <official_title>A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN #1503)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial that will compare survival and sickle related outcomes in
      adolescents and young adults with severe sickle cell disease after bone marrow
      transplantation and standard of care. The primary outcome is 2-year overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective phase II multi-center trial of hematopoietic stem cell transplantation
      or standard of care based on availability of HLA-matched related or unrelated donor after
      confirmation of clinical eligibility. In order to minimize bias assignment to either
      treatment arm, clinical eligibility to both treatment arms are similar and donor availability
      is not known at referral. HLA typing and donor search is initiated upon confirmation of
      clinical eligibility for the study. Additionally, all analyses of primary and secondary
      endpoints will follow the Intent-to-Treat principle to address potential bias introduced by
      participants with donors not proceeding to transplantation or those without a matched donor
      receiving transplantation with less well-matched donors.

      The primary outcome is 2-year overall survival. Our hypothesis is that patients who receive
      bone marrow transplantation will experience early deaths but that this will plateau by 2
      years after transplantation. Patients who receive standard of care will not experience early
      death but will succumb to their disease at a rate much higher than the general population.
      Therefore, the goal of the study is to establish that the difference in the proportion of
      patients surviving is not significantly more than 15% lower in the donor arm at 2-years after
      assignment to treatment arm.

      Secondary endpoints will compare changes in sickle cell disease related events (pulmonary
      hypertension, cerebrovascular events, renal function, avascular necrosis, leg ulcer) and
      functional outcomes [6-minute walk distance (6MWD), health-related quality of life, cardiac
      function, pulmonary function, and mean pain intensity as assessed by a multidimensional
      electronic pain diary] from baseline to 2-years after assignment to treatment arms.

      Additionally for patients assigned to the donor arm and expected to undergo transplantation,
      hematopoietic recovery, graft rejection, acute and chronic graft-versus-host disease, other
      significant transplant-related complications and disease-free survival will be reported.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 Years</time_frame>
    <description>OS will be compared between treatment arms using a point-wise comparison at 2-years, and the survival curves will be estimated using the Kaplan Meier product limit estimator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Sickle Cell Disease (SCD) related events</measure>
    <time_frame>2 Years</time_frame>
    <description>Examination of the occurrence of the SCD-related events will be performed. Exact logistic regression will be used to estimate an odds ratio of each of these events between treatment groups, assuming that at least one event occurs on study in each of the treatment groups, controlling for other patient related characteristics and individual history of the event of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Intensity</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Mean pain intensity assessed by an electronic pain diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>The 6-minute walk distance (6MWD) test will be used to assess exercise capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Cardiac function will be assessed by the change from baseline in Tricuspid regurgitant jet velocity (TRJV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Pulmonary function will be assessed by the change from baseline in Forced Expiratory Volume 1 second (FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>Renal function will be assessed through measurements of albuminuria (urine-albumin creatinine ratio) and serum creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL)</measure>
    <time_frame>Day 28, 1 year, and 2 years</time_frame>
    <description>HRQoL assessed using the NIH's PROMIS 57 instrument.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Donor Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The donor arm will be treated with a preparative regimen of busulfan, fludarabine, and r-ATG before undergoing the bone marrow transplant. Graft-vs-Host-Disease (GVHD) prophylaxis will be tacrolimus combined with methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-Donor Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No-donor arm will continue with standard of care per their SCD physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2).</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-ATG</intervention_name>
    <description>r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg).</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Rabbit antithymocyte globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Transplant</intervention_name>
    <description>Day 0 is the day of bone marrow transplantation.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Hematopoietic Cell Transplant; BMT; HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>Prograf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2.</description>
    <arm_group_label>Donor Arm</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Continue to receive standard of care treatment per patient's SCD physician.</description>
    <arm_group_label>No-Donor Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 15 and &lt; 41 years

          2. Severe sickle cell disease [Hemoglobin SS (Hb SS), Hemoglobin SC (Hb SC) or Hemoglobin
             SBeta thalassemia (Hb Sβ) genotype] with at least 1 of the following manifestations
             (a-e):

               1. Clinically significant neurologic event (stroke) or any neurological deficit
                  lasting &gt; 24 hours;

               2. History of two or more episodes of acute chest syndrome (ACS) in the 2-year
                  period preceding enrollment despite the institution of supportive care measures
                  (i.e. asthma therapy);

               3. Three or more pain crises per year in the 2-year period preceding enrollment
                  (required intravenous pain management in the outpatient or inpatient hospital
                  setting). Clinical documentation of pain management in the inpatient or
                  outpatient setting is required.

               4. Administration of regular RBC transfusion therapy, defined as receiving 8 or more
                  transfusion events per year (in the 12 months before enrollment) to prevent
                  vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest
                  syndrome)

               5. An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥
                  2.7 m/sec.

          3. Adequate physical function as measured by all of the following:

               1. Karnofsky/Lansky performance score ≥ 60

               2. Cardiac function: Left ventricular ejection fraction (LVEF) &gt; 40%; or LV
                  shortening fraction &gt; 26% by cardiac echocardiogram or by Multi Gated Acquisition
                  Scan (MUGA).

               3. Pulmonary function:

             a. Pulse oximetry with a baseline O2 saturation of ≥ 85% b. Diffusing capacity of the
             lung for carbon monoxide (DLCO) &gt; 40% (corrected for hemoglobin) d. Renal function:
             Serum creatinine ≤ 1.5 x the upper limit of normal for age as per local laboratory and
             24 hour urine creatinine clearance &gt;70 mL/min; or GFR &gt; 70 mL/min/1.73 m2 by
             radionuclide Glomerular Filtration Rate (GFR).

             e. Hepatic function:

               1. Serum conjugated (direct) bilirubin &lt; 2x upper limit of normal for age as per
                  local laboratory. Patients with hyperbilirubinemia as a consequence of
                  hyperhemolysis, or who experience a sudden, profound change in the serum
                  hemoglobin after a RBC transfusion are not excluded.

               2. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 5 times
                  upper limit of normal as per local laboratory.

        Additional inclusion required for donor arm participants to proceed with transplant

          1. Liver MRI (≤ 90 days prior to initiation of transplant conditioning) to document
             hepatic iron content is required for participants who are currently receiving ≥8
             packed red blood cell transfusions for ≥1 year or have received ≥20 packed red blood
             cell transfusions (cumulative). Participants who have hepatic iron content ≥7 mg Fe/ g
             liver dry weight by liver MRI must have a liver biopsy and histological
             examination/documentation of the absence of cirrhosis, bridging fibrosis and active
             hepatitis (≤ 90 days prior to initiation of transplant conditioning).

          2. Lack of clinical or radiologic evidence of a recent neurologic event (such as stroke
             or transient ischemic attack) by Cerebral MRI/MRA within 30 days prior to initiating
             transplant conditioning. Subjects with clinical or radiologic evidence of a recent
             neurologic event will be deferred for ≥ 6 months with repeat cerebral MRI/MRA to
             ensure stabilization of the neurologic event prior to proceeding to transplantation

          3. Absence of donor specific HLA antibodies

          4. Documentation of participant's willingness to use approved contraception method until
             discontinuation of all immunosuppressive medications is to be documented in the
             medical record corresponding with the consent conference.

          5. The HLA-matched donor must be medically fit to donate and willing to donate bone
             marrow.

        Exclusion Criteria:

          1. HLA typing prior to referral (consultation with HCT physician). If a subject has had
             HLA typing with accompanying documentation that full siblings were not HLA typed and
             that a search of the unrelated donor registry was not performed the subject will be
             considered eligible. Documentation will be reviewed and adjudicated by the Protocol
             Officer or his/her designee.

          2. Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.

          3. Seropositivity for HIV.

          4. Previous HCT or solid organ transplant.

          5. Participation in a clinical trial in which the patient received an investigational
             drug or device must be discontinued at enrollment.

          6. A history of substance abuse as defined by version IV of the Diagnostic &amp; Statistical
             Manual of Mental Disorders (DSM IV).

          7. Demonstrated lack of compliance with prior medical care as determined by referring
             physician.

          8. Pregnant or breast feeding females.

          9. Inability to receive HCT due to alloimmunization, defined as the inability to receive
             packed red blood cell (pRBC) transfusion therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Eapen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Garrison</last_name>
    <email>bmtctn1503@emmes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Mendizabal, PhD</last_name>
    <email>amendizabal@emmes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Benioff Children's Hospital at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Walters</last_name>
      <email>MWalters@mail.cho.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allistair Abraham</last_name>
      <email>AAbraham@childrensnational.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Gainsville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Castillo</last_name>
      <email>castillopa@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foundation for Sickle Cell Research/Florida Sickle Inc.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gershwin Blyden</last_name>
      <email>GBlyden@fscdr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lazaros Lekakis</last_name>
      <email>LLekakis@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuad El Rassi</last_name>
      <email>fuad.elrassi@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshmanan Krishnamurti</last_name>
      <email>lakshmanan.krishnamurti@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edmund Waller</last_name>
      <email>ewaller@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Pantin</last_name>
      <email>JPANTIN@gru.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Cunninghan</last_name>
      <email>jcunning@peds.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arunkumar Modi</last_name>
      <email>Arunkumar-modi@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lolie Yu</last_name>
      <email>lyu@lsuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oschner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Dalovisio</last_name>
      <email>andrew.dalovisio@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zachariah Defilipp</last_name>
      <email>zdefilipp@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Antin</last_name>
      <email>jantin@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Klings</last_name>
      <email>klingon@bu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Swerdlow</last_name>
      <email>swerdlow@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Schroeder</last_name>
      <email>markschroeder@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Krajewski</last_name>
      <email>JKrajewski@HackensackUMC.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice J Cohen</last_name>
      <email>acohen@barnabashealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center/Albert Einstein School of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murali Janakiram</last_name>
      <email>mjanakir06@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Brooklyn Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayanna Baptiste</last_name>
      <email>amb9075@nyp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Indira Sahdev</last_name>
      <email>ISahdev@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Levine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsiporah Shore</last_name>
      <email>Tbs2001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Kasow</last_name>
      <email>kimberly_kasow@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Sullivan</last_name>
      <email>keith.sullivan@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Devine, MD</last_name>
      <email>steven.devine@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Selby, MD</last_name>
      <phone>405-271-4022</phone>
      <email>George-selby@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trisha Wong</last_name>
      <email>wong@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Olsen</last_name>
      <email>olsont@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Carella</last_name>
      <email>beth.carella@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Jaroscak</last_name>
      <email>jaroscak@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harinder Juneia</last_name>
      <email>harinder.s.juneja@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Premal Lulla</last_name>
      <email>lulla@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uday Popat</last_name>
      <email>upopat@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamila Kindwall-Keller</last_name>
      <email>TLK5DE@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Wiedl</last_name>
      <email>cwiedl@vcu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Young Adults</keyword>
  <keyword>Phase II Trial</keyword>
  <keyword>Hematopoietic Cell Transplantation (HCT)</keyword>
  <keyword>Human Leukocyte Antigen (HLA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

